Bacterial Pneumonia - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Bacterial Pneumonia - Pipeline Review, H2 2016’, provides an overview of the Bacterial Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacterial Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia

The report reviews pipeline therapeutics for Bacterial Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bacterial Pneumonia therapeutics and enlists all their major and minor projects

The report assesses Bacterial Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bacterial Pneumonia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bacterial Pneumonia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bacterial Pneumonia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abera Bioscience AB

Actelion Ltd

Affinivax Inc

Allergan Plc

Aridis Pharmaceuticals LLC

Arsanis Inc

AstraZeneca Plc

Beijing Minhai Biotechnology Co Ltd

Biken Inc

ContraFect Corp ...

Abera Bioscience AB

Actelion Ltd

Affinivax Inc

Allergan Plc

Aridis Pharmaceuticals LLC

Arsanis Inc

AstraZeneca Plc

Beijing Minhai Biotechnology Co Ltd

Biken Inc

ContraFect Corp

Crestone Inc

Daiichi Sankyo Company Ltd

Dong-A Socio Holdings Co Ltd

Double Bond Pharmaceutical International AB

Emergent BioSolutions Inc

FluGen Inc

GlaxoSmithKline Plc

ImmunoBiology Ltd

Indian Immunologicals Ltd

Integrated BioTherapeutics Inc

Kyorin Pharmaceutical Co Ltd

Lascco SA

LegoChem Biosciences Inc

LG Life Science LTD

Liquidia Technologies Inc

MedImmune LLC

Merck & Co Inc

Mucosis BV

Noxxon Pharma AG

Panacea Biotec Ltd

Pfizer Inc

Polyphor Ltd

Prometheon Pharma LLC

Sanofi Pasteur SA

Serum Institute of India Ltd

Shionogi & Co Ltd

SK Chemicals Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Valneva SE

Vaxxilon AG

Virometix AG

Wellstat Vaccines LLC

Wockhardt Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Bacterial Pneumonia Overview 6

Therapeutics Development 7

Bacterial Pneumonia - Therapeutics under Development by Companies 9 ...

Table of Contents

Table of Contents 2

Introduction 5

Bacterial Pneumonia Overview 6

Therapeutics Development 7

Bacterial Pneumonia - Therapeutics under Development by Companies 9

Bacterial Pneumonia - Therapeutics under Investigation by Universities/Institutes 12

Bacterial Pneumonia - Pipeline Products Glance 13

Bacterial Pneumonia - Products under Development by Companies 17

Bacterial Pneumonia - Products under Investigation by Universities/Institutes 21

Bacterial Pneumonia - Companies Involved in Therapeutics Development 22

Bacterial Pneumonia - Therapeutics Assessment 65

Drug Profiles 75

Bacterial Pneumonia - Dormant Projects 185

Bacterial Pneumonia - Discontinued Products 190

Bacterial Pneumonia - Product Development Milestones 191

Appendix 201

List of Tables

List of Tables

Number of Products under Development for Bacterial Pneumonia, H2 2016 17

Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, ...

List of Tables

Number of Products under Development for Bacterial Pneumonia, H2 2016 17

Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Development by Companies, H2 2016 (Contd..1) 20

Number of Products under Development by Companies, H2 2016 (Contd..2) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Late Stage Development, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Development, H2 2016 25

Comparative Analysis by Unknown Stage Development, H2 2016 26

Products under Development by Companies, H2 2016 27

Products under Development by Companies, H2 2016 (Contd..1) 28

Products under Development by Companies, H2 2016 (Contd..2) 29

Products under Development by Companies, H2 2016 (Contd..3) 30

Products under Investigation by Universities/Institutes, H2 2016 31

Bacterial Pneumonia - Pipeline by Abera Bioscience AB, H2 2016 32

Bacterial Pneumonia - Pipeline by Actelion Ltd, H2 2016 33

Bacterial Pneumonia - Pipeline by Affinivax Inc, H2 2016 34

Bacterial Pneumonia - Pipeline by Allergan Plc, H2 2016 35

Bacterial Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 36

Bacterial Pneumonia - Pipeline by Arsanis Inc, H2 2016 37

Bacterial Pneumonia - Pipeline by AstraZeneca Plc, H2 2016 38

Bacterial Pneumonia - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 39

Bacterial Pneumonia - Pipeline by Biken Inc, H2 2016 40

Bacterial Pneumonia - Pipeline by ContraFect Corp, H2 2016 41

Bacterial Pneumonia - Pipeline by Crestone Inc, H2 2016 42

Bacterial Pneumonia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 43

Bacterial Pneumonia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 44

Bacterial Pneumonia - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 45

Bacterial Pneumonia - Pipeline by Emergent BioSolutions Inc, H2 2016 46

Bacterial Pneumonia - Pipeline by FluGen Inc, H2 2016 47

Bacterial Pneumonia - Pipeline by GlaxoSmithKline Plc, H2 2016 48

Bacterial Pneumonia - Pipeline by ImmunoBiology Ltd, H2 2016 49

Bacterial Pneumonia - Pipeline by Indian Immunologicals Ltd, H2 2016 50

Bacterial Pneumonia - Pipeline by Integrated BioTherapeutics Inc, H2 2016 51

Bacterial Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 52

Bacterial Pneumonia - Pipeline by Lascco SA, H2 2016 53

Bacterial Pneumonia - Pipeline by LegoChem Biosciences Inc, H2 2016 54

Bacterial Pneumonia - Pipeline by LG Life Science LTD, H2 2016 55

Bacterial Pneumonia - Pipeline by Liquidia Technologies Inc, H2 2016 56

Bacterial Pneumonia - Pipeline by MedImmune LLC, H2 2016 57

Bacterial Pneumonia - Pipeline by Merck & Co Inc, H2 2016 58

Bacterial Pneumonia - Pipeline by Mucosis BV, H2 2016 59

Bacterial Pneumonia - Pipeline by Noxxon Pharma AG, H2 2016 60

Bacterial Pneumonia - Pipeline by Panacea Biotec Ltd, H2 2016 61

Bacterial Pneumonia - Pipeline by Pfizer Inc, H2 2016 62

Bacterial Pneumonia - Pipeline by Polyphor Ltd, H2 2016 63

Bacterial Pneumonia - Pipeline by Prometheon Pharma LLC, H2 2016 64

Bacterial Pneumonia - Pipeline by Sanofi Pasteur SA, H2 2016 65

Bacterial Pneumonia - Pipeline by Serum Institute of India Ltd, H2 2016 66

Bacterial Pneumonia - Pipeline by Shionogi & Co Ltd, H2 2016 67

Bacterial Pneumonia - Pipeline by SK Chemicals Co Ltd, H2 2016 68

Bacterial Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 69

Bacterial Pneumonia - Pipeline by Valneva SE, H2 2016 70

Bacterial Pneumonia - Pipeline by Vaxxilon AG, H2 2016 71

Bacterial Pneumonia - Pipeline by Virometix AG, H2 2016 72

Bacterial Pneumonia - Pipeline by Wellstat Vaccines LLC, H2 2016 73

Bacterial Pneumonia - Pipeline by Wockhardt Ltd, H2 2016 74

Assessment by Monotherapy Products, H2 2016 75

Assessment by Combination Products, H2 2016 76

Number of Products by Stage and Target, H2 2016 78

Number of Products by Stage and Mechanism of Action, H2 2016 80

Number of Products by Stage and Route of Administration, H2 2016 82

Number of Products by Stage and Molecule Type, H2 2016 84

Bacterial Pneumonia - Dormant Projects, H2 2016 195

Bacterial Pneumonia - Dormant Projects (Contd..1), H2 2016 196

Bacterial Pneumonia - Dormant Projects (Contd..2), H2 2016 197

Bacterial Pneumonia - Dormant Projects (Contd..3), H2 2016 198

Bacterial Pneumonia - Dormant Projects (Contd..4), H2 2016 199

Bacterial Pneumonia - Discontinued Products, H2 2016 200

List of Figures

List of Figures

Number of Products under Development for Bacterial Pneumonia, H2 2016 17

Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, ...

List of Figures

Number of Products under Development for Bacterial Pneumonia, H2 2016 17

Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Late Stage Development, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Products, H2 2016 25

Assessment by Monotherapy Products, H2 2016 75

Assessment by Combination Products, H2 2016 76

Number of Products by Top 10 Targets, H2 2016 77

Number of Products by Stage and Top 10 Targets, H2 2016 77

Number of Products by Top 10 Mechanism of Actions, H2 2016 79

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 79

Number of Products by Routes of Administration, H2 2016 81

Number of Products by Stage and Routes of Administration, H2 2016 81

Number of Products by Top 10 Molecule Types, H2 2016 83

Number of Products by Stage and Top 10 Molecule Types, H2 2016 83

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports